Key result
Aspirin 325 mg twice daily for 7 days significantly reduced platelet ATP release in both healthy smokers (P=0.01) and nonsmokers (P=0.003).
Why the study?
Does aspirin reduce platelet aggregation in healthy smoking and nonsmoking male volunteers compared to ticlopidine?
RCT (n=18)
randomized, crossover
No
Does aspirin reduce platelet aggregation in healthy smoking and nonsmoking male volunteers compared to ticlopidine?
Aspirin 325 mg twice daily for 7 days significantly reduces platelet aggregation in healthy males regardless of smoking status.
Answers are grounded in this paper and cite their sources.
Aspirin 325 mg BID achieves consistent platelet inhibition irrespective of smoking; confirms efficacy on ATP release in healthy males and warrants patient studies.
OBJECTIVE: To assess the relative antiaggregatory ability of aspirin on platelets of smoking and nonsmoking healthy volunteers. DESIGN: Prospective, randomized, crossover study. SETTING: Tertiary-care teaching institution. SUBJECTS: Eighteen healthy smoking and nonsmoking male volunteers. INTERVENTIONS: Each subject received aspirin 325 mg or ticlopidine 250 mg bid as an active control for 7 days in a crossover manner separated by a 1-month washout period. Whole blood platelet aggregation was measured on four occasions, twice at baseline and once after each drug treatment. OUTCOME MEASUREMENT: Whole blood ex vivo platelet aggregation in terms of impedance (omega) and adenosine triphosphate (ATP) release (nmol), as assessed using Lumi-aggregometry. RESULTS: Aspirin was associated with significantly less ATP release in both smokers (p = 0.01) and nonsmokers (p = 0.003). No significant differences in platelet aggregation were found between smokers and nonsmokers at baseline or with any treatment phases. Sixty-seven percent and 17% of volunteers receiving ticlopidine and aspirin, respectively, reported adverse effects. CONCLUSIONS: Twice-daily administration of aspirin for 7 days to healthy volunteers was well tolerated and also reduced platelet aggregation significantly regardless of smoking status.
No takes yet. Share an insight, caveat, or question.
Chant et al. (1997) conducted an RCT in Healthy volunteers (n=18). Aspirin vs. Ticlopidine 250 mg bid was evaluated on Whole blood ex vivo platelet aggregation (impedance and ATP release) (p=0.01 (smokers), 0.003 (nonsmokers)). Aspirin 325 mg twice daily for 7 days significantly reduced platelet ATP release in both healthy smokers (P=0.01) and nonsmokers (P=0.003).
Synapse has enriched 10 related papers. Consider them for comparative context: